Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Novo Nordisk (CPSE:NOVO B) reported positive phase 2 data for its investigational drug amycretin (zenagamtide), a dual GLP-1 and amylin receptor agonist.
The phase 2 trial in adults with type 2 diabetes showed strong glycemic control and significant weight loss, with no clear plateau at higher doses.
Safety and efficacy data support moving amycretin into phase 3 trials for both diabetes and obesity.
This is the first major update on this new pipeline candidate as Novo Nordisk seeks to compete in the next generation of obesity and diabetes treatments.
Novo Nordisk, the company behind established GLP-1 therapies for diabetes and obesity, is now highlighting amycretin as a potential next step in its pipeline. With competition in weight loss and metabolic treatments increasing, a dual-acting candidate targeting both GLP-1 and amylin receptors gives the company another angle within its core therapeutic focus.
For investors tracking CPSE:NOVO B, amycretin adds an additional element of optionality within the broader obesity and diabetes drug space. As the program moves toward phase 3, attention is likely to focus on how this candidate might sit alongside or differ from Novo Nordisk’s existing treatments if it eventually reaches the market.
Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.
CPSE:NOVO B Earnings & Revenue Growth as at Jun 2026
For you as an investor, the amycretin phase 2 data matters because it shows Novo Nordisk working on a next wave of GLP 1 based therapies beyond current semaglutide products. The trial showed up to a 1.71 percentage point reduction in A1C from a 7.8% baseline and up to 14.6% weight loss at 40 mg versus 2.1% with placebo over 36 weeks, with a dose dependent profile and no clear weight loss plateau at higher doses. That combination of sugar control and double digit weight reduction in adults already on metformin, and in many cases SGLT2 inhibitors, points to a candidate designed for tougher to treat metabolic patients. In a competitive field that includes Eli Lilly and newer entrants such as Viking Therapeutics, having a first in class dual GLP 1 and amylin receptor agonist in both injectable and planned oral forms gives Novo Nordisk another potential product family within diabetes and obesity care rather than relying only on semaglutide extensions.
Story Continues
How This Fits Into The Novo Nordisk Narrative
The glycemic and weight loss data from amycretin support the existing narrative that new products and formats in metabolic disease are central to long term development in GLP 1 therapies.
The need to fund phase 3 programs for another complex peptide could challenge the narrative that earnings resilience will come only from current Wegovy and Ozempic lines without further investment and execution risk.
The dual GLP 1 and amylin mechanism, and the potential for both injectable and oral routes, add a dimension to the story that is not fully reflected in high level obesity and diabetes discussions focused mainly on single agonists.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk to help decide what it’s worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Positive phase 2 data do not remove the risk that later stage amycretin trials in broader obesity or diabetes populations could deliver less favorable efficacy or safety outcomes than expected, especially as doses increase.
⚠️ Developing another high profile weight loss and diabetes drug may add to concentration risk around GLP 1 type products at a time when analysts have already flagged earnings quality concerns linked to this class.
🎁 If amycretin progresses through phase 3, Novo Nordisk could have a differentiated dual agonist that sits alongside Wegovy and other GLP 1 products, potentially widening its addressable metabolic disease market.
🎁 A first in class dual GLP 1 and amylin receptor agonist may help Novo Nordisk defend share against Eli Lilly and other peers by offering an additional treatment choice for patients who need both strong glycemic control and substantial weight reduction.
What To Watch Going Forward
From here, it is worth watching how Novo Nordisk designs the amycretin phase 3 program, including whether trials focus on tougher to treat diabetes populations, obesity only groups, or both, and how endpoints balance A1C, weight loss, and safety. Any head to head data versus existing GLP 1 drugs from Novo Nordisk or competitors such as Eli Lilly would also be important for understanding positioning. In addition, pay close attention to whether the company advances oral as well as injectable versions, since that choice could influence how amycretin fits alongside the Wegovy pill and other oral GLP 1 therapies.
To stay informed on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to keep up with the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com